TY  - GEN
AU  - Kröger,N
AU  - Schetelig,J
AU  - Zabelina,T
AU  - Krüger,W
AU  - Renges,H
AU  - Stute,N
AU  - Schrum,J
AU  - Kabisch,H
AU  - Siegert,W
AU  - Zander,A R
TI  - A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome
SN  - 0268-3369
PY  - 2001///1214
KW  - Adult
KW  - Anemia, Refractory, with Excess of Blasts
KW  - genetics
KW  - Antilymphocyte Serum
KW  - administration & dosage
KW  - Bone Marrow
KW  - pathology
KW  - Busulfan
KW  - Cell Count
KW  - Chromosomes, Human, Pair 7
KW  - Cyclophosphamide
KW  - Disease-Free Survival
KW  - Feasibility Studies
KW  - Graft Survival
KW  - Graft vs Host Disease
KW  - mortality
KW  - Hematopoietic Stem Cell Transplantation
KW  - Hepatic Veno-Occlusive Disease
KW  - etiology
KW  - Histocompatibility
KW  - Humans
KW  - Infections
KW  - Karyotyping
KW  - Methotrexate
KW  - Middle Aged
KW  - Monosomy
KW  - Myelodysplastic Syndromes
KW  - Recurrence
KW  - Survival Rate
KW  - T-Lymphocytes
KW  - Tissue Donors
KW  - Transplantation Conditioning
KW  - adverse effects
KW  - Transplantation, Homologous
KW  - Treatment Outcome
KW  - Vidarabine
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1038/sj.bmt.1703215
ER  -